Comparative efficacy of topical microbicides in the prevention of HIV transmission – results from a systematic review and network meta-analysis
DOI:
https://doi.org/10.15584/ejcem.2025.1.9Keywords:
HIV, topical microbicides, vaginal microbicidesAbstract
Introduction and aim. Preventing new HIV infections is crucial, particularly for women and girls at high risk. Vaginal microbi cides offer a female-controlled HIV prevention method. This systematic review evaluated the comparative efficacy of topical microbicides in preventing HIV transmission.
Material and methods. Electronic databases were searched up to May 2024 for randomized controlled trials (RCTs) comparing topical microbicides versus placebo/no treatment in sexually active women. The primary outcome was the incidence of HIV. A random effects network meta-analysis (NMA) was employed. Relative ranking was assessed using surface under the cumula tive ranking curve (SUCRA) probabilities.
Analysis of literature. Thirteen RCTs were included in the review comparing the dapivirine ring, the tenofovir gel, BufferGel, PRO 2000, Carraguard, cellulose sulfate, or SAVVY against placebos. Compared to placebo, only dapivirine significantly reduced HIV incidence (risk ratio (RR) 0.71 [95% CI 0.56 to 0.91]). Dapivirine was superior to BufferGel (RR 0.61 [95% CI 0.39 to 0.94]) and SAVVY (RR 0.52 [95% CI 0.28 to 0.97]). Dapivirine ranked highest in efficacy (SUCRA=0.93), followed by tenofovir (SUCRA=0.76). In general, consistent network results with some small study effects.
Conclusion. This study supports the use of the vaginal dapivirine ring for HIV prevention over SAVVY or BufferGel. More high-quality trials are needed to validate the efficacy of tenofovir gel.
Downloads
References
Global HIV & AIDS statistics- Fact sheet. https://www.unaids.org/en/resources/fact-sheet. Accessed 30 June 2024.
Pre-exposure prophylaxis (PrEP). https://www.cdc.gov/hiv/risk/prep/index.html. Accessed June 30, 2024.
World Health Organization. Microbicides. https://www.who.int/hiv/topics/microbicides/microbicides/en/. Accessed June 30, 2024.
Relaño-Rodríguez I, Muñoz-Fernández MÁ. Emergence of Nanotechnology to Fight HIV Sexual Transmission: The Trip of G2-S16 Polyanionic Carbosilane Dendrimer to Possible Pre-Clinical Trials. Int J Mol Sci. 2020;21(24):9403. doi: 10.3390/ijms21249403
Rodríguez-Izquierdo I, Sepúlveda-Crespo D, Lasso JM, Resino S, Muñoz-Fernández MÁ. Baseline and time-updated factors in preclinical development of anionic dendrimers as successful anti-HIV-1 vaginal microbicides. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2022;14(3):e1774.
Obiero J, Ogongo P, Mwethera PG, Wiysonge CS. Topical microbicides for preventing sexually transmitted infections. Cochrane Database Syst Rev. 2021;3(100909747):CD007961. Doi: 10.1002/14651858. CD007961.pub3
Baeten JM, Palanee-Phillips T, Brown ER, et al. Use of a Vaginal Ring Containing Dapivirine for HIV-1 Prevention in Women. N Engl J Med. 2016;375(22):2121-3132. doi: 10.1056/NEJMoa1506110
Hutton B, Salanti G, Caldwell DM, et al. The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann Intern Med. 2015;162(11):777-784. doi: 10.7326/M14-2385
Nonoxynol-9 ineffective in preventing HIV infection. https://www.who.int/news/item/28-06-2002-nonoxynol-9-ineffective-in-preventing-hiv-infection. Accessed June 30, 2024.
Higgins JPT, Thomas J, Chandler J, Li T, Page MJ, Welch VA. Cochrane Handbook for Systematic Reviews of Interventions version 6.4 (updated August 2023). Cochrane. 2023.
Higgins JPT, Altman DG, Gøtzsche PC, et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928. doi: 10.1136/bmj.d5928
DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7(3):177-188.
Chaimani A, Higgins JPT, Mavridis D, Spyridonos P, Salanti G. Graphical tools for network meta-analysis in STATA. PloS One. 2013;8(10):e76654. doi: 10.1371/journal.pone.0076654
Bucher HC, Guyatt GH, Griffith LE, Walter SD. The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials. J Clin Epidemiol. 1997;50(6):683-691. doi: 10.1016/s0895-4356(97)00049-8
Salanti G, Ades AE, Ioannidis JPA. Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial. J Clin Epidemiol. 2011;64(2):163-171. doi: 10.1016/j.jclinepi.2010.03.016
Dechartres A, Altman DG, Trinquart L, Boutron I, Ravaud P. Association between analytic strategy and estimates of treatment outcomes in meta-analyses. JAMA. 2014;312(6):623-630. doi: 10.1001/jama.2014.8166
Skoler-Karpoff S, Ramjee G, Ahmed K, et al. Efficacy of Carraguard for prevention of HIV infection in women in South Africa: a randomised, double-blind, placebo-controlled trial. Lancet. 2008 Dec 6;372(9654):1977-1987. doi: 10.1016/S0140-6736(08)61842-5
Expanded safety and acceptability of the candidate vaginal microbicide Carraguard® in South Africa. Contraception. 2010;82(6):563-571.
Peterson L, Nanda K, Opoku BK, et al. SAVVY® (C31G) Gel for Prevention of HIV infection in Women: A Phase 3, Double-Blind, Randomized, Placebo-Controlled Trial in Ghana. PLoS ONE. 2007;2(12):e1312. doi: 10.1371/journal.pone.0001312
Nel A, van Niekerk N, Kapiga S, et al. Safety and Efficacy of a Dapivirine Vaginal Ring for HIV Prevention in Women. N Engl J Med. 2016;375(22):2133-2143. doi: 10.1056/NEJMoa1602046
McCormack S, Ramjee G, Kamali A, et al. PRO2000 vaginal gel for prevention of HIV-1 infection (Microbicides Development Programme 301): a phase 3, randomised, double-blind, parallel-group trial. Lancet. 2010;376(9749):1329-1337. doi: 10.1016/S0140-6736(10)61086-0
Marrazzo JM, Ramjee G, Richardson BA, et al. Tenofovir-based preexposure prophylaxis for HIV infection among African women. N Engl J Med. 2015;372(6):509-518. doi: 10.1056/NEJMoa1402269
Halpern V, Ogunsola F, Obunge O, et al. Effectiveness of cellulose sulfate vaginal gel for the prevention of HIV infection: results of a Phase III trial in Nigeria. PloS One. 2008;3(11):e3784. doi: 10.1371/journal.pone.0003784
Feldblum PJ, Adeiga A, Bakare R, et al. SAVVY vaginal gel (C31G) for prevention of HIV infection: a randomized controlled trial in Nigeria. PloS One. 2008;3(1):e1474. Doi: 10.1371/journal.pone.0001474
Delany-Moretlwe S, Lombard C, Baron D, et al. Tenofovir 1% vaginal gel for prevention of HIV-1 infection in women in South Africa (FACTS-001): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Infect Dis. 2018;18(11):1241-1250. doi: 10.1016/S1473-3099(18)30428-6
Abdool Karim Q, Abdool Karim SS, Frohlich JA, et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science. 2010;329(5996):1168-1174. doi: 10.1126/science.1193748
Abdool Karim SS, Richardson BA, Ramjee G, et al. Safety and effectiveness of BufferGel and 0.5% PRO2000 gel for the prevention of HIV infection in women. AIDS. 2011;25(7):957-966. doi: 10.1097/QAD.0b013e32834541d9
Van Damme L, Govinden R, Mirembe FM, et al. Lack of effectiveness of cellulose sulfate gel for the prevention of vaginal HIV transmission. N Engl J Med. 2008;359(5):463-472. doi: 10.1056/NEJMoa0707957
Baryakova TH, Pogostin BH, Langer R, McHugh KJ. Overcoming barriers to patient adherence: the case for developing innovative drug delivery systems. Nat Rev Drug Discov. 2023;22(5):387-409. doi: 10.1038/s41573-023-00670-0
Zhernov YV, Petrova VO, Simanduyev MY, et al. Microbicides for Topical HIV Immunoprophylaxis: Current Status and Future Prospects. Pharmaceuticals. 2024;17(6):668. doi: 10.3390/ph17060668
ICYMI: Research Roundup from AIDS 2024. https://www.hiv.gov/blog/icymi-research-roundup-from-aids-2024. Accessed August 28, 2024.
PK, Safety Study of 90-Day Use of Vaginal Rings Containing Dapivirine and Levonorgestrel. https://clinicaltrials.gov/study/NCT05041699. Accessed August 28, 2024.
Musekiwa A, Fernando NB, Abariga SA. Effectiveness of vaginal microbicides in preventing HIV transmission. Trop Med Int Health. 2020;25(7):790-802. doi: 10.1111/tmi.13401
Pre-Exposure Prophylaxis. https://www.hiv.gov/hiv-basics/hiv-prevention/using-hiv-medication-to-reduce-risk/pre-exposure-prophylaxis. Accessed June 30, 2024.
International Partnership for Microbicides. Women & HIV/AIDS [Internet]. Available from: https://www.ipmglobal.org/women-hiv-aids. Accessed June 30, 2024.
Gatali M, Archibald C. Women and HIV. BMC Womens Health. 2004;4(1):S27.
Baeten JM, Palanee-Phillips T, Mgodi NM, et al. Safety, uptake, and use of a dapivirine vaginal ring for HIV-1 prevention in African women (HOPE): an open-label, extension study. Lancet HIV. 2021;8(2):e87-e95. doi: 10.1016/S2352-3018(20)30304-0
Nel A, van Niekerk N, Van Baelen B, et al. Safety, adherence, and HIV-1 seroconversion among women using the dapivirine vaginal ring (DREAM): an open-label, extension study. Lancet HIV. 2021;8(2):e77-e86. doi: 10.1016/S2352-3018(20)30300-3
Vaginal ring to reduce the risk of HIV infection for women in non-EU countries with high disease burden. https://www.ema.europa.eu/en/news/vaginal-ring-reduce-risk-hiv-infection-women-non-eu-countries-high-disease-burden. Accessed June 30, 2024.
WHO recommends the dapivirine vaginal ring as a new choice for HIV prevention for women at substantial risk of HIV infection. https://www.who.int/news/item/26--01-2021-who-recommends-the-dapivirine-vaginal-ring-as-a-new-choice-for-hiv-prevention-for-women-at-substantial-risk-of-hiv-infection. Accessed June 30, 2024.
International Partnership for Microbicides. Dapivirine Ring Fast Facts. https://www.ipmglobal.org/our-work/our-products/dapivirine-ring. Accessed June 30, 2024.
Glaubius R, Ding Y, Penrose KJ, et al. Dapivirine vaginal ring for HIV prevention: modelling health outcomes, drug resistance and cost-effectiveness. J Int AIDS Soc. 2019;22(5):e25282.
Reidy M, Gardiner E, Pretorius C, Glaubius R, Torjesen K, Kripke K. Evaluating the potential impact and cost-effectiveness of dapivirine vaginal ring pre-exposure prophylaxis for HIV prevention. PloS One. 2019;14(6):e0218710. Doi: 10.1371/journal.pone.0218710
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 European Journal of Clinical and Experimental Medicine
This work is licensed under a Creative Commons Attribution 4.0 International License.
Our open access policy is in accordance with the Budapest Open Access Initiative (BOAI) definition: this means that articles have free availability on the public Internet, permitting any users to read, download, copy, distribute, print, search, or link to the full texts of these articles, crawl them for indexing, pass them as data to software, or use them for any other lawful purpose, without financial, legal, or technical barriers other than those inseparable from having access to the Internet itself.
All articles are published with free open access under the CC-BY Creative Commons attribution license (the current version is CC-BY, version 4.0). If you submit your paper for publication by the Eur J Clin Exp Med, you agree to have the CC-BY license applied to your work. Under this Open Access license, you, as the author, agree that anyone may download and read the paper for free. In addition, the article may be reused and quoted provided that the original published version is cited. This facilitates freedom in re-use and also ensures that Eur J Clin Exp Med content can be mined without barriers for the research needs.
